The Team2018-07-04T14:24:29+00:00

The Peak Proteins Team

team-mark

Protein Production

Mark Abbott  PhD

Protein expression and purification specialist

 

20 years in the pharmaceutical industry with a comprehensive knowledge of protein production,  small molecule and biologics research areas. Mark also has extensive experience in line and project management. After his departure from AstraZeneca, Mark founded Peak Proteins to apply his accumulated knowledge to solve scientific problems.

Use of a Protein Engineering Strategy to Overcome Limitations in the Production of ‘Difficult to Express’ Recombinant Proteins
Biotechnolgy and Bioengineering 2017 114(10):2348-2359.
Hirra Hussain, David I Fisher, W Mark Abbott, Robert G Roth, Alan J Dickson

Cellularly active N-hydroxyurea FEN1 inhibitors block substrate entry to the active site
Nat Chem Biol.  2016 12, 815–821
Exell JC, Thompson MJ, Finger LD, Shaw SJ, Debreczeni J, Ward TA, McWhirter C, Siöberg CL, Molina DM, Abbott WM, Jones CD, Nissink JW, Durant ST, Grasby JA

Optimisation of a simple method to transiently transfect a CHO cell line in high-throughput and at large scale
Protein Expression and Purification 2015 116, 113–119.
Mark Abbott, Brian Middleton, Fredrik Kartberg, Josefine Claesson, Robert Roth, David Fisher

Current approaches to fine mapping of antigen antibody interactions.
Immunology 2014 142, 526–535.
WM Abbott, M Damschroder, DC Lowe

Characterization of the complex formed between a potent neutralizing ovine-derived polyclonal anti-TNFalpha Fab fragment and human TNFalpha.
Bioscience Reports 2013 33 e00060
WM Abbott, M Snow, S Eckersley, J Renshaw, G Davies, RA Norman, P Ceuppens, J Slootstra, JJ Benschop, Y Hamuro, JE Lee, P Newham

Co-expression of protein phosphatases in insect cells affects phosphorylation status and expression levels of proteins.
Protein Expression and Purification 2012 83, 217-225.
Brading RL, Abbott WM, Green I, Davies A, McCall EJ

Structure of IL-17A in complex with a potent, fully human neutralizing antibody.
J Mol Biol 2009 394(5):905-921.
Gerhardt S, Abbott WM, Hargreaves D, Pauptit RA, Davies RALangham C, Barker W, Aziz A, Snow MJ, Dawson S, Welsh F, Wilkinson T,Vaugan T, Beste G, Bishop S, Popovic B, Rees G, Sleeman M, Tuske SJ, Coales SJ, Hamuro Y, Russell C

team-ian

Protein Expression

Ian Hampton  BSc

Expert in recombinant protein expression

 

With more than 20 years experience in the pharmaceutical industry, Ian has an across-the-board knowledge of protein expression using E. coli, insect and mammalian cells. Ian gained his experience during his time working at AstraZeneca at Alderley Park.

Structural biology

Tina Howard  PhD

Protein crystallisation specialist

 

20 years experience in academia and the pharmaceutical industry working on protein structures. Tina has a strong track record of successful crystallisation of numerous proteins and protein ligand complexes. Before joining AstraZeneca, Tina has worked on a variety of structural projects at the Universities of Glasgow, Manchester, UMIST, Warwick and Oxford

Structure-Guided Discovery of Potent and Selective Inhibitors of ERK1/2 from a Modestly Active and Promiscuous Chemical Start Point
J. Med. Chem.,201760: 3438–3450.
RA. Ward, P Bethel, C Cook, E Davies, J Debreczeni, G Fairley, L Feron, V Flemington, MA. Graham, R Greenwood, N Griffin, L Hanson, P Hopcroft, TD Howard, J Hudson, M James, CD. Jones, CR. Jones, S Lamont, R Lewis, N Lindsay, K Roberts, I Simpson, S St-Gallay, S Swallow, J Tang, M Tonge, Z Wang, & B Zhai

Design, Synthesis and Biological Activity of Substrate Competitive SMYD2 Inhibitors
J. Med. Chem., 2016 59: 11079-11097.
SD Cowen, D Russell, LA Dakin, H Chen, NA Larsen, R Godin, S Throner, X Zheng, A Molina, J Wu, T Cheung, T Howard, R Garcia-Arenas, N Keen, CS Pendleton, JA Pietenpol, & AD Ferguson

Structural basis of Lewisb antigen binding by the Helicobacter pylori adhesin BabA
Science Advances 2015, 1, e1500315
N Hage, T Howard, C Phillips, C Brassington, R Overman, J Debreczeni, P Gellert, S Stolnik, GS Winkler, FH Falcone

From Fragments to Leads: Novel Bacterial NAD+-Dependent DNA Ligase Inhibitors
Tetrahedron Letters 2015, 66, 3108-12.
M Hale, C Brassington; D Carcanague; K Embrey; CJ Eyermann; RA Giacobbe; L Gingipali; M Gowravaram, J Harang; T. Howard; G Ioannidis; H Jahic; A Kutschke; VA  Laganas; J Loch; MD Miller; KE Murphy-Benenato; H Oguto; L Otterbein; SJ Patel, AB Shapiro; PA Boriack-Sjodin

Structure-guided Design of Highly Selective and Potent Covalent Inhibitors of ERK1/2
J Med Chem, 2015, 58, 4790–4801.
RA Ward, N Colclough, M Challinor, JE Debreczeni, K Eckersley, G Fairley, L Feron, V Flemington, MA Graham, R Greenwood, P Hopcroft, TD Howard, M James, CD. Jones, CR. Jones, J Renshaw, K Roberts, L Snow, M Tonge and K Yeung

Pyrimidinone Nicotinamide Mimetics as Selective Tankyrase and Wnt Pathway Inhibitors Suitable for in Vivo Pharmacology
ACS Medicinal Chemistry Letters, 2015, 6, 254-259.
J Johannes, L Almeida; B Barlaam, PA Boriack-Sjodin, R Casella; R Croft, A Dishington, L Gingipalli, CA Gu, J Hawkins, J Holmes, T Howard, J Huang, S Ioannidis, S Kazmirski, M Lamb, T McGuire, J Moore, D Ogg, A Patel, K Pike, T Pontz, G Robb, N Su, H Wang, X Wu, H-J Zhang, Y Zhang, X Zheng, T Wang

Discovery of 1-methyl-1H-imidazole derivatives as potent Jak2 inhibitors 
J. Med. Chem., 2014, 57 (1), pp 144–158.
Q Su, S Ioannidis, C Chuaqui, L Almeida, M Alimzhanov, G Bebernitz, K Bell, M Block, T Howard, S Huang, D Huszar, JA. Read, C Rivard Costa, J Shi, M Su, M Ye, and M Zinda

Structural Biology

Derek Ogg  PhD

Protein Crystallographer

 

More than 20 years experience in academia, large and small pharma. In all of these environments, Derek has used crystallography & computational chemistry approaches to support structure based drug design. He has most recently worked at AstraZeneca, with previous posts at the Structural Genomics Consortium, Pharmacia and Biovitrum.

Discovery of N-{4-[(6,7-dimethoxyquinazolin-4-yl)oxy]phenyl}-2-[4-(propan-2-yl)-1H-1,2,3-triazol-1-yl]acetamide (AZD3229), a potent pan-KIT mutant inhibitor for the treatment of gastrointestinal stromal tumors.
J. Med Chem. 2018, (submitted).
Kettle JG, Anjum R, Barry E, Bhavsar D, Brown C, Boyd S, Campbell A, Goldberg K, Grondine M, Guichard S, Hardy CJ, Hunt T, Jones RDO, Li X, Moleva O, Ogg D, Overman RC, Packer MJ, Pearson S, Schimpl M, Shao W, Smith A, Smith JM, Stead D, Stokes S, Tucker M, Ye Y.

Potent and selective bivalent inhibitors of BET bromodomains.
Nat Chem Biol. 2016, 12(12):1097-1104.
Waring MJ, Chen H, Rabow AA, Walker G, Bobby R, Boiko S, Bradbury RH, Callis R, Clark E, Dale I, Daniels DL, Dulak A, Flavell L, Holdgate G, Jowitt TA, Kikhney A, McAlister M, Méndez J, Ogg D, Patel J, Petteruti P, Robb GR, Robers MB, Saif S, Stratton N, Svergun DI, Wang W, Whittaker D, Wilson DM, Yao Y.

Discovery of a novel allosteric inhibitor-binding site in ERK5: comparison with the canonical kinase hinge ATP-binding site.
Acta Crystallogr D Struct Biol. 2016, 72:682-93.
Chen H, Tucker J, Wang X, Gavine PR, Phillips C, Augustin MA, Schreiner P, Steinbacher S, Preston M, Ogg D. 

Landscape of activating cancer mutations in FGFR kinases and their differential responses to inhibitors in clinical use.
Oncotarget. 2016. 7(17):24252-68.
Patani H, Bunney TD, Thiyagarajan N, Norman RA, Ogg D, Breed J, Ashford P, Potterton A, Edwards M, Williams SV, Thomson GS, Pang CS, Knowles MA, Breeze AL, Orengo C, Phillips C, Katan M.

Predicting the relative binding affinity of mineralocorticoid receptor antagonists by density functional methods.
J Comput Aided Mol Des. 2015, 29(12):1109-22.
Roos K, Hogner A, Ogg D, Packer MJ, Hansson E, Granberg KL, Evertsson E, Nordqvist A.

Pyrimidinone Nicotinamide Mimetics as Selective Tankyrase and Wnt Pathway Inhibitors Suitable for in Vivo Pharmacology
ACS Medicinal Chemistry Letters, 2015, 6: 254-259
J Johannes, L Almeida; B Barlaam, PA Boriack-Sjodin, R Casella; R Croft, A Dishington, L Gingipalli, CA Gu, J Hawkins, J Holmes, T Howard, J Huang, S Ioannidis, S Kazmirski, M Lamb, T McGuire, J Moore, D Ogg, A Patel, K Pike, T Pontz, G Robb, N Su, H Wang, X Wu, H-J Zhang, Y Zhang, X Zheng, T Wang

Identification and optimisation of 3,3-dimethyl-azetidin-2-ones as potent and selective inhibitors of 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1).
Med Chem Commun, 2014 5:57-63.
McCoull W, Augustin M, Blake C., Ertan A., Kilgour E., Krapp S, Moore JE., Newcombe NJ, Packer M, Rees A, Revill J, Scott JS, Selmi N, Gerhardt S, Ogg DJ, Steinbacher S, Whittamore PR.,

Thiazolopyridone ureas as DNA gyrase B inhibitors: optimization of antitubercular activity and efficacy.
Bioorg Med Chem Lett. 2014, 24: 870-9
Kale RR, Kale MG, Waterson D, Raichurkar A, Hameed SP, Manjunatha MR, Kishore Reddy BK, Malolanarasimhan K, Shinde V, Koushik K, Jena LK, Menasinakai S, Humnabadkar V, Madhavapeddi P, Basavarajappa H, Sharma S, Nandishaiah R, Mahesh Kumar KN, Ganguly S, Ahuja V, Gaonkar S, Naveen Kumar CN, Ogg D, Boriack-Sjodin PA, Sambandamurthy VK, de Sousa SM, Ghorpade SR.

Thiazolopyridine Ureas as Novel Antitubercular Agents acting through Inhibition of DNA Gyrase B.
J. Med Chem. 2013, 14: 8834-48.
Kale MG, Raichurkar A, Hameed S, Waterson D, McKinney D,  Manjunatha MR, Kranthi U, Koushik K, Jena L, Shinde V, Rudrapatana S, Humnabadkar V, Madhavapeddi P, Basavarajappa H, Ghosh A, Ramya VK,  Guptha S, Sharma S, Vachaspathi P, Kumar KNM, Giridhar J, Reddy J, Panduga V, Ganguly S, Ahuja V, Gaonkar S, Kumar CNN, Ogg DJ, Tucker J, Boriack-Sjodin A, de Sousa SM, Sambandamurthy VK and Ghorpade SR.

team-giles

Protein Production

Giles Hassall  BSc

Protein purification specialist

 

Giles has considerable experience working with proteins, having spent much of his career in the pharmaceutical industry. He has worked on a wide variety of drug discovery programs, supplying proteins for assay screens and structural study campaigns.

Early in his career he spent 2 years at Rhone-Poulenc Rorer then moved on to AstraZeneca, where he spent 22 years. This was followed by a short spell in academia, working at the University of Manchester for 3½ years, before joining Peak Proteins.

Structures of the Human Poly (ADP-Ribose) Glycohydrolase Catalytic Domain Confirm Catalytic Mechanism and Explain Inhibition by ADP-HPD Derivatives
PLoS One. 2012; 7(12): e50889
JA Tucker, N Bennett, C Brassington, ST. Durant, G Hassall, G Holdgate, M McAlister, JW Nissink, C Truman and M Watson

Design and synthesis of novel lactate dehydrogenase A inhibitors by fragment-based lead generation.
J Med Chem. 2012 Apr 12;55(7):3285-306. doi: 10.1021/jm201734r. Epub 2012 Mar 26.
Ward RA, Brassington C, Breeze AL, Caputo A, Critchlow S, Davies G, Goodwin L, Hassall G, Greenwood R, Holdgate GA, Mrosek M, Norman RA, Pearson S, Tart J, Tucker JA, Vogtherr M, Whittaker D, Wingfield J, Winter J, Hudson K.

Protein Production

Anna Valentine  BSc

Protein purification specialist

 

With over 20 years experience in the Pharmaceutical industry, Anna has worked primarily in the field of protein purification during her career, developing protein purification methods and supplying proteins to support a wide range of drug discovery projects for assays and structural studies.

Anna worked at AstraZeneca in the Protein Science group for 18 years, followed by a 5 year spell within QA/QC labs developing and validating methods for small drug molecules before joining Peak Proteins.

Design and Discovery of a novel class of triazolones as Checkpoint Kinase inhibitors—Hit to lead exploration.
Bioorganic & Medicinal Chemistry Letters 20 (2010) 5133–5138.
V Oza, S Ashwell, P Brassil, J Breed, C Deng, J Ezhuthachan,
H Haye, C Horn, James Janetka, Paul Lyne, N Newcombe, L Otterbien, M Pass, J Read, S Roswell, M Su, D Toader, D Yu, Y Yu, A Valentine, P Webborn, A White, S Zabludoff, X Zheng

Structural Biology and Protein Production

Helen Gingell  MSc

Crystallisation specialist

Helen has many years of experience in both the production of pure protein and protein crystallisation for structural studies to support structure-based drug design across a range of clinical targets. She has experience of successful fragment-based-screening by protein crystallography.

Helen worked for AstraZeneca in their Protein Science and Structural Biology groups for 15 years. This was followed by a short spell of 1½ years at the University of Manchester, in research involving tissue culture and microbiology, before joining Peak Proteins.

(Maiden name McMiken)

Tetrahydroisoquinoline Phenols: Selective Estrogen Receptor Downregulator Antagonists with Oral Bioavailability in Rat
ACS Medicinal Chemistry Letters2015, 7, 94-99
James S. Scott, Andrew Bailey, Robert D. M. Davies, Sébastien L. Degorce, Philip A. MacFaul, Helen Gingell, Thomas Moss, Richard A. Norman, Jennifer H. Pink, Alfred A. Rabow, Bryan Roberts, and Peter D. Smith

Optimization of a Novel Binding Motif to (E)-3-(3,5-Difluoro-4-((1R,3R)-2-(2-fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)phenyl)acrylic Acid (AZD9496), a Potent and Orally Bioavailable Selective Estrogen Receptor Downregulator and Antagonist.
J Med Chem., 2015, 58(20), 8128-8140
De Savi C, Bradbury RH, Rabow AA, Norman RA, de Almeida C, Andrews DM, Ballard P, Buttar D, Callis RJ, Currie GS, Curwen JO, Davies CD, Donald CS, Feron LJ, Gingell H, Glossop SC, Hayter BR, Hussain S, Karoutchi G, Lamont SG, MacFaul P, Moss TA, Pearson SE, Tonge M, Walker GE, Weir HM, Wilson Z

Structure Guided Lead Generation for M. tuberculosis Thymidylate Kinase (Mtb TMK): Discovery of 3-Cyanopyridone and 1,6-Naphthyridin-2-one as Potent Inhibitors
J Med Chem 2015, 58 (2), 753–766
Naik M, Raichurkar A, Bandodkar BS, Varun BV, Bhat S, Kalkhambkar R, Murugan K, Menon R, Bhat J, Paul B, Iyer H, Hussein S, Tucker JA, Vogtherr M, Embrey KJ, McMiken H, Prasad S, Gill A, Ugarkar BG, Venkatraman J, Read J, Panda M.

Optimization of pyrrolamides as mycobacterial GyrB ATPase inhibitors: structure-activity relationship and in vivo efficacy in a mouse model of tuberculosis
Antimicrob. Agents Chemother, 2014, 58(1), 61-70
Hameed, S.P., Solapure S, Mukherjee K, Nandi V, Waterson D, Shandil R, Balganesh M, Sambandamurthy VK, Raichurkar AK, Deshpande A, Ghosh A, Awasthy D, Shanbhag G, Sheikh G, McMiken H, Puttur J, Reddy J, Werngren J, Read J, Kumar M, R M, Chinnapattu M, Madhavapeddi P, Manjrekar P, Basu R, Gaonkar S, Sharma S, Hoffner S, Humnabadkar V, Subbulakshmi V, Panduga V.

Pyridomycin bridges the NADH- and substrate-binding pockets of the enoyl reductase InhA
Nature Chemical Biology, 2014, 10, 96–98
Hartkoorn RC, Pojer F, Read JA, Gingell H, Neres J, Horlacher OP, Altmann KH, Cole ST

Methyl-Thiazoles: A Novel Mode of Inhibition with the Potential to Develop Novel Inhibitors Targeting InhA in Mycobacterium tuberculosis
J Med Chem, 2013, 56 (21), 8533–8542
Shirude PS, Madhavapeddi P, Naik M, Murugan K, Shinde V, Nandishaiah R, Bhat J, Kumar A, Hameed S, Holdgate G, Davies G, McMiken H, Hegde N, Ambady A, Venkatraman J, Panda M, Bandodkar B, Sambandamurthy VK, Read JA.

Protein Expression

Catherine Geh  BSc

Expert in recombinant protein expression

 

Catherine has over 18 years experience of in vitro Oncology drug discovery in the pharmaceutical industry. She has worked at all phases of the drug discovery process, developing high quality cellular screening assays and clinical biomarker assays on a variety of platforms, for a number of key Oncology programs.

She worked at AstraZeneca for 18 years, most recently in the Oncology Translational Science group, before joining Peak Proteins.

High-Level Clonal FGFR Amplification and Response to FGFR Inhibition in a Translational Clinical Trial
Cancer Discov. 2016 Aug; 6(8): 838–851.
Alex Pearson, Elizabeth Smyth, Irina S. Babina, Maria Teresa Herrera-Abreu, Noelia Tarazona, Clare Peckitt, Elaine Kilgour, Neil R. Smith, Catherine Geh, Claire Rooney, Ros Cutts, James Campbell, Jian Ning, Kerry Fenwick, Amanda Swain, Gina Brown, Sue Chua, Anne Thomas, Stephen R.D. Johnston, Mazhar Ajaz, Katherine Sumpter, Angela Gillbanks, David Watkins, Ian Chau, Sanjay Popat, David Cunningham, and Nicholas C. Turner

Characterization of FGFR1 Locus in sqNSCLC Reveals a Broad and Heterogeneous Amplicon
PLoS One. 2016 Feb 23;11(2):e0149628. doi: 10.1371/journal.pone.0149628. eCollection 2016.
Rooney C, Geh C, Williams V, Heuckmann JM, Menon R, Schneider P, Al-Kadhimi K, Dymond M, Smith NR, Baker D, French T, Smith PD, Harrington EA, Barrett JC, Kilgour E.

Evaluating Robustness and Sensitivity of the NanoString Technologies nCounter Platform to Enable Multiplexed Gene Expression Analysis of Clinical Samples
Cancer Res. 2015 Jul 1;75(13):2587-93. doi: 10.1158/0008-5472.CAN-15-0262. Epub 2015 Jun 11.
Veldman-Jones MH, Brant R, Rooney C, Geh C, Emery H, Harbron CG, Wappett M, Sharpe A, Dymond M, Barrett JC, Harrington EA, Marshall G.

Protein Expression

Juli Warwicker  PhD

Protein Purification Specialist

 

Juli has 15 years experience working in the pharmaceutical industry, specialising in the supply of recombinant proteins and validated tool antibodies to support drug discovery projects, from target validation through to clinical trials.

Immediately before joining Peak Proteins Juli worked at AstraZeneca for 15 years, based in Reagent Supply teams. Prior to working at AstraZeneca, she spent several years in academia and government science, researching membrane lipases and storage proteins.

The Use of Antibodies in Small-Molecule Drug Discovery
J. Biomol. Screen 201419 829-38.
Marsden CJ, Eckersley S, Hebditch, M, Kvist, AJ, Milner R, Mitchell D, Warwicker J, Marely A.

Validation of BRCA1 antibody MS 110 and the utility of BRCA1as a patient selction biomarker in immunohistological analysis of breast and ovarian tumours
Virchows Arch. 2013, 462 269-79.
Milner R, Wombwell H, Eckersley S, Barnes D, Warwicker J, Van drop E, Rowlinson R, Dearden S, Hughes G, Harbron C, Wellings B, Hodgson D, Womack C, Gary N, Lau A, O’Conor MJ, Marsden CJ, & Kvist, AJ.

Business Development

Hazel Weir  PhD

Scientific Business Development

 

Hazel’s early career in the pharmaceutical industry was focused on the application of new gene expression systems for target validation and protein production. Following a transition into Oncology drug discovery, Hazel provided bioscience expertise and leadership from lead candidate through to Phase I clinical trials.

After leaving AstraZeneca last year, Hazel has undertaken project management work for a local charity before joining Peak Proteins.

Activating ESR1 Mutations Differentially Affect the Efficacy of ER Antagonists
Cancer Discov. 2017, 7(3):277-287.
Weiyi Toy, Hazel Weir, Pedram Razavi, Mandy Lawson, Anne U. Goeppert, Anne Marie Mazzola, Aaron Smith, Joanne Wilson, Christopher Morrow, Wai Lin Wong, Elisa De Stanchina, Kathryn E. Carlson, Teresa S. Martin, Sharmeen Uddin, Zhiqiang Li, Sean Fanning, John A. Katzenellenbogen, Geoffrey Greene, José Baselga and Sarat Chandarlapaty.

Mutation site and context dependent effects of ESR1 mutation in genome-edited breast cancer cell models
Breast Cancer Research 2017, 19(1):60.
Amir Bahreini, Zheqi Li, Peilu Wang,Kevin M. Levine, Nilgun Tasdemir, Lan Cao, Hazel M. Weir, Shannon L. Puhalla, Nancy E. Davidson, Andrew M. Stern, David Chu, Ben Ho Park, Adrian V. Lee, Steffi Oesterreich

AZD9496: An Oral Estrogen Receptor Inhibitor That Blocks the Growth of ER-Positive and ESR1-Mutant Breast Tumors in Preclinical Models
Cancer Research 2016, 6(11):3307-18.
Hazel M. Weir, Robert H. Bradbury, Mandy Lawson, Alfred A. Rabow, David Buttar, Rowena J. Callis, Jon O. Curwen, Camila de Almeida, Peter Ballard, Michael Hulse, Craig S. Donald, Lyman J.L. Feron, Galith Karoutchi, Philip MacFaul, Thomas Moss, Richard A. Norman, Stuart E. Pearson, Michael Tonge, Gareth Davies, GraemeE. Walker, Zena Wilson, Rachel Rowlinson, Steve Powell, Claire Sadler, Graham Richmond, Brendon Ladd, Ermira Pazolli, AnneMarie Mazzola, Celina D’Cruz and Chris De Savi

Effective combination therapies in preclinical endocrine resistant breast cancer models harboring ER mutations
Oncotarget. 2016 7(34):54120-54136.
Ladd B, Mazzola AM, Bihani T, Lai Z, Bradford J, Collins M, Barry E, Goeppert AU, Weir HM, Hearne K, Renshaw JG, Mohseni M, Hurt E, Jalla S, Bao H, Hollingsworth R, Reimer C, Zinda M, Fawell S, D’Cruz CM.

Protein Production

Jon Renshaw BSc

Protein Purification Specialist

 

Jon has spent over 24 years working in drug discovery, during which time he gathered a wealth of experience in protein expression, purification and characterisation. He has supported projects across various disease areas and has spent time working in both assay development and protein crystallisation, giving him a rounded perspective of what is needed for these protein deliverables. Jon joins Peak Protein after working for AstraZeneca in protein supply, which most recently included providing mass spectrometry support to enable whole protein characterisation.

Identification and Characterization of Dual Inhibitors of the USP25/28 Deubiquitinating Enzyme Subfamily
ACS Chem Biol.2017, 12(12):3113-3125.
Wrigley JD, Gavory G, Simpson I, Preston M, Plant H, Bradley J, Goeppert AU, Rozycka E, Davies G, Walsh J, Valentine A, McClelland K, Odrzywol KE, Renshaw J, Boros J, Tart J, Leach L, Nowak T, Ward RA, Harrison T, Andrews DM.

Structure and characterization of a high affinity C5a monoclonal antibody that blocks binding to C5aR1 and C5aR2 receptors
MAbs 2018 10(1):104-117.
Colley CS, Popovic B, Sridharan S, Debreczeni JE, Hargeaves D, Fung M, An LL, Edwards B, Arnold J, England E, Eghobamien L, Sivars U, Flavell L,Renshaw J, Wickson K, Warrener P, Zha J, Bonnell J, Woods R, Wilkinson T, Dobson C, Vaughan TJ.

Effective combination therapies in preclinical endocrine resistant breast cancer models harboring ER mutations.
Oncotarget. 2016, 7(34):54120-54136.
Ladd B, Mazzola AM, Bihani T, Lai Z, Bradford J, Collins M, Barry E, Goeppert AU, Weir HM, Hearne K, Renshaw JG, Mohseni M, Hurt E, Jalla S, Bao H, Hollingsworth R, Reimer C, Zinda M, Fawell S, D’Cruz CM.

Backbone resonance assignments for the PHD-Bromo dual-domain of the human chromatin reader TRIM24
Biomol NMR Assign. 2016 Apr;10(1):207-11.
Walser R, Renshaw J, Milbradt AG.

Structure-Guided Design of Highly Selective and Potent Covalent Inhibitors of ERK1/2
J Med Chem. 2015 58(11):4790-801.
Ward RA, Colclough N, Challinor M, Debreczeni JE, Eckersley K, Fairley G, Feron L, Flemington V, Graham MA, Greenwood R, Hopcroft P, Howard TD, James M, Jones CD, Jones CR, Renshaw J, Roberts K, Snow L, Tonge M, Yeung K.

Improved expression and purification of the Helicobacter pylori adhesin BabA through the incorporation of a hexa-lysine tag
Protein Expr Purif. 2015, 106:25-30.
Hage N, Renshaw JG, Winkler GS, Gellert P, Stolnik S, Falcone FH.

Characterization of the complex formed between a potent neutralizing ovine-derived polyclonal anti-TNFα Fab fragment and human TNFα
Biosci Rep. 2013, 33(4):655-654.
Abbott WM, Snow M, Eckersley S, strong>Renshaw J, Davies G, Norman RA, Ceuppens P, Slootstra J, Benschop JJ, Hamuro Y, Lee JE, Newham P.

Mass Spectrometry

Rachel Rowlinson BSc

Specialist in Protein Mass Spectrometry

Rachel has over 20 years experience in the pharmaceutical industry, working primarily in protein analysis including N-terminal sequencing and protein mass spectrometry.  Rachel has a wealth of experience in biological mass spectrometry particularly in proteomics and protein characterisation and joins us from AstraZeneca’s Protein Science group.

Rapid isolation and enrichment of extracellular vesicle preparations using anion exchange chromatography
Sci Rep. 2018 8(1):5730.
Heath N, Grant L, De Oliveira TM, Rowlinson R, Osteikoetxea X, Dekker N, Overman R.

Pyruvate dehydrogenase kinase 4 exhibits a novel role in the activation of mutant KRAS, regulating cell growth in lung and colorectal tumour cells.
Oncogene 2017 Nov 2;36(44):6164-6176.
Trinidad AG, Whalley N, Rowlinson R, Delpuech , Dudley P, Rooney C, Critchlow SE.

Identification of DYRK1B as a substrate of ERK1/2 and characterisation of the kinase activity of DYRK1B mutants from cancer and metabolic syndrome.
Cell Mol Life Sci. 2016 73(4):883-900.
Ashford AL, Dunkley TP, Cockerill M, Rowlinson RA, Baak LM, Gallo R, Balmanno K, Goodwin LM, Ward RA, Lochhead PA, Guichard S, Hudson K, Cook SJ.

AZD9496: An Oral Estrogen Receptor Inhibitor That Blocks the Growth of ER-Positive and ESR1-Mutant Breast Tumors in Preclinical Models
Cancer Research 2016, 6(11):3307-18.
Hazel M. Weir, Robert H. Bradbury, Mandy Lawson, Alfred A. Rabow, David Buttar, Rowena J. Callis, Jon O. Curwen, Camila de Almeida, Peter Ballard, Michael Hulse, Craig S. Donald, Lyman J.L. Feron, Galith Karoutchi, Philip MacFaul, Thomas Moss, Richard A. Norman, Stuart E. Pearson, Michael Tonge, Gareth Davies, GraemeE. Walker, Zena Wilson, Rachel Rowlinson, Steve Powell, Claire Sadler, Graham Richmond, Brendon Ladd, Ermira Pazolli, AnneMarie Mazzola, Celina D’Cruz and Chris De Savi.

AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer
Cancer. Discov. 2014 4(9):1046-6.
Darren A.E. Cross, Susan E. Ashton, Serban Ghiorghiu, Cath Eberlein, Caroline A. Nebhan, Paula J. Spitzler, Jonathon P. Orme, M. Raymond V. Finlay, Richard A. Ward, Martine J. Mellor, Gareth Hughes, Amar Rahi, Vivien N. Jacobs, Monica Red Brewer, Eiki Ichihara, Jing Sun, Hailing Jin, Peter Ballard, Katherine Al-Kadhimi, Rachel Rowlinson, Teresa Klinowska, Graham H.P. Richmond, Mireille Cantarini, Dong-Wan Kim, Malcolm R. Ranson and William Pao